Tag Archives: Sacituzumab Govitecan

November, 2018

July, 2018

January, 2018

May, 2017

  • 5 May

    Seattle Genetics Terminates License Agreement with Immunomedics

    BOTHELL, Wash.–(BUSINESS WIRE)–Seattle Genetics, Inc. (Nasdaq: SGEN), a global biotechnology company, today announced that it has agreed to terminate its license agreement with Immunomedics, Inc. (Nasdaq: IMMU) for sacituzumab govitecan (IMMU-132) and settle the related litigation. The license agreement had not yet closed due to legal action brought by an …

April, 2017

February, 2017

February, 2016